Clinical profile of prasugrel, a novel thienopyridine - 08/08/11
, Eric R. Bates, MD, FACC b, Theodore A. Bass, MD, FACC aRésumé |
Prasugrel (CS-747; LY-640315) is a novel, third-generation oral thienopyridine that is a specific, irreversible antagonist of the platelet adenosine 5′-diphosphate P2Y12 receptor. Laboratory results with prasugrel support more potent antiplatelet effects, a lower incidence of interpatient variability in antiplatelet response, and a reduced time to onset of antiplatelet activity compared with clopidogrel. Phase II results indicate that prasugrel produces a greater antiplatelet effect than clopidogrel administered even at doses higher than the currently approved 300-mg loading dose and 75-mg/d maintenance dose. Recent phase III data show that prasugrel is superior to clopidogrel in preventing ischemic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention, although this was associated with a greater risk of bleeding.
Le texte complet de cet article est disponible en PDF.Plan
| Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, NJ); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsippany, NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsippany, NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Eric R. Bates, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Sanofi-Aventis; Hoffmann-La Roche (Nutley, NJ). Honoraria/Advisory board: Eli Lilly Co; The Medicines Company; Daiichi Sankyo, Inc.; Medicure Pharma (Winnipeg, Manitoba, Canada). Research Grants: Eli Lilly and Company. Theodore A. Bass, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Eli Lilly and Company; Daiichi Sankyo, Inc. |
Vol 156 - N° 2S
P. 16S-22S - août 2008 Retour au numéro
Article précédent
- Pharmacology of emerging novel platelet inhibitors
- Dominick J. Angiolillo, Piera Capranzano
- Clinical overview of promising nonthienopyridine antiplatelet agents
- Dominick J. Angiolillo, Luis A. Guzman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?